Skip to main content

Peer Review reports

From: Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

Original Submission
5 Dec 2023 Submitted Original manuscript
22 Dec 2023 Reviewed Reviewer Report - MAISARAH BINTI JALALONMUHALI
4 Jan 2024 Reviewed Reviewer Report - Cheney Drew
30 Jan 2024 Author responded Author comments - Lillian Streichart
Resubmission - Version 2
30 Jan 2024 Submitted Manuscript version 2
15 Feb 2024 Reviewed Reviewer Report - Cheney Drew
23 Feb 2024 Reviewed Reviewer Report - MAISARAH BINTI JALALONMUHALI
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
26 Feb 2024 Editorially accepted
22 Mar 2024 Article published 10.1186/s13063-024-08020-0

You can find further information about peer review here.

Back to article page